Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: A meta-analysis of randomized control trials

Diabetic Medicine

Volumn 33, Issue 3, 2016, Pages 280-289

  Seidu, Samuel ^a,b   Achana, F A ^c   Gray, L J ^a,d   Davies, M J ^a,b   Khunti, K ^a,b  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PHENFORMIN; TOLBUTAMIDE;

ARTICLE; BEHAVIOR CHANGE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DISEASE DURATION; DISEASE SEVERITY; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; INTENSIVE CARE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; MORTALITY; MULTIMODALITY CANCER THERAPY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84958766686     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12885     Document Type: Article

References (31)

1. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB et al. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
2. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
3. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. Glucose control and vascular complications in veterans with Type 2 diabetes. N Engl J Med 2009; 360: 129-162.
4. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B et al. Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in Type 2 diabetes: meta-analysis of randomised controlled trials. Br Med J 2011; 343: d4169.
5. Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373(9677): 1765-1772.
6. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycemia in Type 2 diabetes: a patient-centered approach. Diabetes Care 2012; 35: 1364-1379.
7. Turnbull F, Abraira C, Anderson R, Byington R, Chalmers J, Duckworth W et al. Intensive glucose control and macrovascular outcomes in Type 2 diabetes. Diabetologia 2009; 52: 2288-2298.
8. Sardar P, Udell JA, Chatterjee S, Bansilal S, Mukherjee D, Farkouh ME. Effect of intensive versus standard blood glucose control in patients with Type 2 diabetes mellitus in different regions of the world: systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2015; 4: e001577.
9. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for Type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015; 3: 356-366.
10. Turner RC, Holman RR, Cull CA, Stratton IM, Matthews DR, Frighi V et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
11. Gaede P, Lund-Andersen H, Parving H, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N Engl J Med 2008; 358: 580-591.
12. Hsieh A, Ong PX, Molyneaux L, McGill MJ, Constantino M, Wu T et al. Age of diabetes diagnosis and diabetes duration associate with glycated haemoglobin. Diabetes Res Clin Pract 2014; 104: e1-4.
13. Duckworth WC, Abraira C, Moritz TE, Davis SN, Emanuele N, Goldman S et al. The duration of diabetes affects the response to intensive glucose control in Type 2 subjects: the VA Diabetes Trial. J Diabetes Complicat 2011; 25: 355-361.
14. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
15. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GEHM, Sandbaek A et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with Type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011; 378: 156-167.
16. Rahman M, Simmons R, Hennings S, Wareham N, Griffin S. How much does screening bring forward the diagnosis of Type 2 diabetes and reduce complications? Twelve year follow-up of the Ely cohort. Diabetologia 2012; 55: 1651-1659.
17. Higgins JP, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley Online Library, 2008.
18. Sterne JA, Sutton AJ, Terrin N, Jones DR, Lau J, Carpenter J et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002.
19. Lunn D, Jackson C, Best N, Thomas A, Spiegelhalter D. The BUGS Book: a practical introduction to Bayesian analysis. Boca Raton, FL: CRC Press, 2012.
20. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: V. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976; 25: 1129-1153.
21. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: V. Evaluation of phenformin therapy. Diabetes 1975; 24: 65-184.
22. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
23. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VIII. Evaluation of insulin therapy: final report. Diabetes 1982; 31: 1-81.
24. Yoshii H, Onuma T, Yamazaki T, Watada H, Matsuhisa M, Matsumoto M et al. Effects of pioglitazone on macrovascular events in patients with Type 2 diabetes mellitus at high risk of stroke: the Profit-j Study. J Atheroscler Thromb 2014; 21: 563-573.
25. Rachmani R, Slavachevski I, Berla M, Frommer-Shapira R, Ravid M. Teaching and motivating patients to control their risk factors retards progression of cardiovascular as well as microvascular sequelae of Type 2 diabetes mellitus - a randomized prospective 8 years follow-up study. Diabetic Med 2005; 22: 410-414.
26. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33: 983-990.
27. Sharp SJ, Thompson SG. Analysing the relationship between treatment effect and underlying risk in meta-analysis: comparison and development of approaches. Stat Med 2000; 19: 3251-3274.
28. Yeap BB, McCaul KA, Flicker L, Hankey GJ, Almeida OP, Golledge J et al. Diabetes, myocardial infarction and stroke are distinct and duration-dependent predictors of subsequent cardiovascular events and all-cause mortality in older men. J Clin Endocrin Metab 2015; 100: 1038-1047.
29. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-1418.
30. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
31. Ross S, Gerstein HC, Eikelboom J, Anand SS, Yusuf S, Pare G. Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. Eur Heart J 2015; 36: 1454-1462.